Format

Send to

Choose Destination
Am J Reprod Immunol. 2012 Jun;67(6):491-7. doi: 10.1111/j.1600-0897.2011.01101.x. Epub 2012 Jan 9.

Lipoxin A4 inhibits the development of endometriosis in mice: the role of anti-inflammation and anti-angiogenesis.

Author information

1
Department of Obstetrics and Gynecology, 1st Affiliated Hospital, Wenzhou Medical College, Zhejiang, China.

Abstract

PROBLEM:

To evaluate the effects of the anti-inflammatory and anti-angiogenic roles of LXA4 on endometriosis in mice.

METHOD OF STUDY:

Endometriosis was induced in 40 mice and separated into two groups. LXA4 group was administered by LXA4 for 3 weeks. The endometriotic lesions were counted, measured, and identified by pathology. The presence of a panel of pro-inflammatory factors was assessed by real-time RT-PCR, and enzyme-linked immunoassay, the mRNA, protein levels of matrix metalloproteinase (MMPs), and vascular endothelial growth factor (VEGF) were determined by real-time RT-PCR and immunohistochemistry; the activity of MMPs was evaluated by gelatin zymography.

RESULTS:

Treatment with LXA4 significantly inhibited endometriotic lesion development (13.58 ± 4.01 mm(2) in LXA4 group and 23.20 ± 7.49 mm(2) , P = 0.0002), downregulated pro-inflammatory factors, suppressed the activity of MMP9, and reduced the VEGF levels associated with endometriosis in mice.

CONCLUSION:

LXA4 may inhibit the progression of endometriosis possibly by anti-inflammation and anti-angiogenesis.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center